Eyepoint vs Traws Pharma
Eyepoint is the larger business, with $31.4m of revenue in fiscal 2025 against $2.8m for Traws Pharma (11.2 times as much). Traws Pharma grew faster (1134.5% against -27.5%). Traws Pharma kept more of each dollar of sales as profit: a net margin of 328.7% against -739.4%.
| Latest fiscal year | EyepointEYPT, 2025 | Traws PharmaTRAW, 2025 |
|---|---|---|
| Revenue | $31.4m | $2.8m |
| Revenue growth | -27.5% | 1134.5% |
| Net income | −$232m | $9.2m |
| Operating margin | -776.0% | -640.7% |
| Net margin | -739.4% | 328.7% |
| Return on equity | -72.2% | — |
| Free cash flow | −$243m | −$20.8m |
| Cash | $102m | $3.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 214 | — |
| Market value | $31.4m | $4.6m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 2 buys, 11 sales | 1 buys, 0 sales |